← All trials
NCT05811676
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2023
- Primary completion
- Jul 1, 2024
- Completion date
- Sep 1, 2024
- First posted
- Apr 13, 2023
- Last posted
- Aug 15, 2023
- Enrollment
- 1680
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Medical UniversityLead sponsor
- Sun Yat-Sen UniversityCollaborator
- Xinjiang Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Foshan Women and Children HospitalCollaborator
- Guangzhou Medical UniversityReponsible party - principal investigator
- Guangzhou Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Peking UniversityCollaborator
- Shenzhen UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Guangzhou Medical UniversitySponsor investigator
- Dalian Maternity and Child Care HospitalCollaborator
- Hunan Provincial Maternal and Child Health Care HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.